{
  "abstract": "Plain Language Summary: What is this summary about?\n\nHARMONi is a study of a new treatment for people with advanced or metastatic non–small cell lung cancer (NSCLC) with an activating mutation in the epidermal growth factor receptor (EGFR) gene. The study included participants in Asia, Europe, and North America whose cancer had gotten worse after treatment with an EGFR tyrosine kinase inhibitor (EGFR-TKI).\n\nIvonescimab is a new type of cancer treatment that helps the immune system recognize and attack tumor cells. It also blocks the formation of new blood vessels that tumors need to grow. HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy.\n\nWhat were the results?\n\nParticipants who were given ivonescimab plus chemotherapy lived longer without their cancer getting worse or spreading (called progression-free survival). The median progression-free survival was 6.8 months with ivonescimab plus chemotherapy compared with 4.4 months with placebo plus chemotherapy. This difference was statistically significant. The median overall survival, or the amount of time participants lived after starting treatment, was longer with ivonescimab plus chemotherapy (median, 16.8 months) compared with placebo plus chemotherapy (median, 14.0 months); however, this difference was not statistically significant.\n\nTwo hundred and seven of 218 participants (95%, or about 9 out of every 10) who were given ivonescimab plus chemotherapy and 203 of 218 participants (93%, or about 9 out of every 10) who were given placebo plus chemotherapy had side effects related to their treatment. Common side effects with ivonescimab plus chemotherapy included changes in blood cell levels, nausea, decreased appetite, vomiting, and changes in liver enzymes. Some participants in each treatment group had severe or serious side effects. Four participants who received ivonescimab plus chemotherapy and five who received placebo plus chemotherapy died from treatment-related side effects.\n\nWhat do the results mean?\n\nFor participants whose advanced NSCLC had gotten worse after EGFR-TKI treatment, ivonescimab plus chemotherapy resulted in a reduced risk of cancer getting worse or spreading by nearly half, compared with placebo plus chemotherapy. Overall survival was longer with ivonescimab plus chemotherapy; however, the difference was not statistically significant. Side effects occurred in a similar proportion of participants in both treatment groups. Most side effects could be managed without significantly impacting the participants’ quality of life or requiring treatment discontinuation.\n\nClinical trial number: NCT06396065",
  "abstract_shown": true,
  "affiliations": [
    "Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
    "European Institute of Oncology IRCCS, Milan, Italy",
    "Sun Yat-sen University Cancer Center, Guangzhou, China",
    "British Columbia Cancer and University of British Columbia, Vancouver, BC, Canada",
    "Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Spain",
    "Hospital General Universitario Gregorio Marañón, Madrid, Spain",
    "UC San Diego Moores Cancer Center, San Diego, CA, USA",
    "Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy",
    "Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada",
    "Regina Elena National Cancer Institute, Rome, Italy",
    "Institut Curie, Paris, France",
    "Lung Unit, Royal Marsden Hospital, London, UK",
    "Division of Clinical Studies, Institute of Cancer Research, London, UK",
    "Hunan Cancer Hospital, Changsha, China",
    "Fujian Provincial Tumor Hospital, Fuzhou, China",
    "The Second Hospital of Anhui Medical University, Hefei, China",
    "The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China",
    "Renmin Hospital of Wuhan University, Wuhan, China",
    "Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada",
    "Service de Pneumologie, CHI Créteil, Créteil, France",
    "Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain",
    "Hospital Universitario A Coruña, Health Research Institute, Coruña, Spain",
    "SCRI Oncology Partners, Rocky Mountain Cancer Centers, Lone Tree, CO, USA",
    "Valkyrie Clinical Trials, Los Angeles, CA, USA",
    "Virginia Cancer Specialists Research Institute, Fairfax, VA, USA",
    "NEXT Oncology, Fairfax, VA, USA",
    "Léon Bérard Cancer Center of Lyon, Lyon, France",
    "UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, USA",
    "Summit Therapeutics, Palo Alto, CA, USA",
    "UCLA Health, Los Angeles, CA, USA"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 35,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xiuning Le"
    },
    {
      "affs": [
        1
      ],
      "name": "Antonio Passaro"
    },
    {
      "affs": [
        2
      ],
      "name": "Yuanyuan Zhao"
    },
    {
      "affs": [
        2
      ],
      "name": "Yan Huang"
    },
    {
      "affs": [
        3
      ],
      "name": "Janessa Laskin"
    },
    {
      "affs": [
        4
      ],
      "name": "Delvys Rodriguez-Abreu"
    },
    {
      "affs": [
        5
      ],
      "name": "Antonio Calles"
    },
    {
      "affs": [
        6
      ],
      "name": "Lyudmila Bazhenova"
    },
    {
      "affs": [
        7
      ],
      "name": "Giuseppe Lo Russo"
    },
    {
      "affs": [
        8
      ],
      "name": "Natasha B. Leighl"
    },
    {
      "affs": [
        9
      ],
      "name": "Federico Cappuzzo"
    },
    {
      "affs": [
        10
      ],
      "name": "Nicolas Girard"
    },
    {
      "affs": [
        11,
        12
      ],
      "name": "Sanjay Popat"
    },
    {
      "affs": [
        2
      ],
      "name": "Wenfeng Fang"
    },
    {
      "affs": [
        13
      ],
      "name": "Yongzhong Luo"
    },
    {
      "affs": [
        14
      ],
      "name": "Zhiyong He"
    },
    {
      "affs": [
        15
      ],
      "name": "Hui Zhao"
    },
    {
      "affs": [
        16
      ],
      "name": "Mingjun Li"
    },
    {
      "affs": [
        17
      ],
      "name": "Qibin Song"
    },
    {
      "affs": [
        2
      ],
      "name": "Hongyun Zhao"
    },
    {
      "affs": [
        18
      ],
      "name": "Haidar El Darsa"
    },
    {
      "affs": [
        19
      ],
      "name": "Isabelle Monnet"
    },
    {
      "affs": [
        20
      ],
      "name": "Manuel Cobo Dols"
    },
    {
      "affs": [
        21
      ],
      "name": "Rosario García Campelo"
    },
    {
      "affs": [
        22
      ],
      "name": "Robert Jotte"
    },
    {
      "affs": [
        23
      ],
      "name": "David Berz"
    },
    {
      "affs": [
        24,
        25
      ],
      "name": "Alexander Spira"
    },
    {
      "affs": [
        26
      ],
      "name": "Maurice Pérol"
    },
    {
      "affs": [
        27
      ],
      "name": "Misako Nagasaka"
    },
    {
      "affs": [
        28
      ],
      "name": "Howard West"
    },
    {
      "affs": [
        28
      ],
      "name": "Jianling Li"
    },
    {
      "affs": [
        28
      ],
      "name": "Fong Clow"
    },
    {
      "affs": [
        28
      ],
      "name": "Amy C. Moore"
    },
    {
      "affs": [
        29
      ],
      "name": "Jonathan Goldman"
    },
    {
      "affs": [
        2
      ],
      "name": "Zhang Li"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/976ccke4y22q8.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2749355",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757635/",
  "id": "976ccke4y22q8",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2749355",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Plain Language Summary"
    ],
    [
      "heading",
      "Plain Language Summary of Publication"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7225318551",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2749355?needAccess=true",
  "pmcid": "PMC13757635",
  "pmid": "43013362",
  "published": "2026-11-04",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/976ccke4y22q8.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:14Z",
      "native_id": "PMC13757635",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2749355"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study",
  "title_text": "Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:14Z",
  "url": "https://research.draconitic.com/paper/976ccke4y22q8",
  "venue": "Future Oncology",
  "versions": []
}